Randomized control trial of Celecoxib in prevention of complications after partial splenic embolization

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000062

Enrollment

Unknown

Registered

2008-02-24

Start date

2008-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperspleism

Interventions

A:Placebo

B:200mg oral celecoxib 1 day before PSE nd continued on 6 days after PSE

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male patients in hospital aged from 18 to 70; 2. History of cirrhosis with splenomegaly dignosed by radiology; 3. Marked depression of circulating erythrocytes, platelets and leucocytes; 4. No contraindications of partial splenic embolization; 5. Participant agreed and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. end-stage liver disease; 2. Prothrombin time less than 70% of normal; 3. Anaphylactic reactions caused by Sulpha.

Design outcomes

Primary

Measure	Time frame
complications in patients with PSE / both treatmen;infracted region and volume of spleen / measured by computed tomography after PSE;	—

Countries

China

Contacts

Public ContactChengwei Tang

chengweitang123@126.com+86 028 81812275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026